280 related articles for article (PubMed ID: 23529824)
1. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
Dhillon S
Drugs; 2013 Apr; 73(5):475-85. PubMed ID: 23529824
[TBL] [Abstract][Full Text] [Related]
2. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J; Campone M; Piccart M; Burris HA; Rugo HS; Sahmoud T; Noguchi S; Gnant M; Pritchard KI; Lebrun F; Beck JT; Ito Y; Yardley D; Deleu I; Perez A; Bachelot T; Vittori L; Xu Z; Mukhopadhyay P; Lebwohl D; Hortobagyi GN
N Engl J Med; 2012 Feb; 366(6):520-9. PubMed ID: 22149876
[TBL] [Abstract][Full Text] [Related]
3. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Beaver JA; Park BH
Future Oncol; 2012 Jun; 8(6):651-7. PubMed ID: 22764762
[TBL] [Abstract][Full Text] [Related]
4. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
[TBL] [Abstract][Full Text] [Related]
6. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Yardley DA; Noguchi S; Pritchard KI; Burris HA; Baselga J; Gnant M; Hortobagyi GN; Campone M; Pistilli B; Piccart M; Melichar B; Petrakova K; Arena FP; Erdkamp F; Harb WA; Feng W; Cahana A; Taran T; Lebwohl D; Rugo HS
Adv Ther; 2013 Oct; 30(10):870-84. PubMed ID: 24158787
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Noguchi S; Masuda N; Iwata H; Mukai H; Horiguchi J; Puttawibul P; Srimuninnimit V; Tokuda Y; Kuroi K; Iwase H; Inaji H; Ohsumi S; Noh WC; Nakayama T; Ohno S; Rai Y; Park BW; Panneerselvam A; El-Hashimy M; Taran T; Sahmoud T; Ito Y
Breast Cancer; 2014 Nov; 21(6):703-14. PubMed ID: 23404211
[TBL] [Abstract][Full Text] [Related]
10. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
11. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
12. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
13. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
14. [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
Ito Y; Masuda N; Iwata H; Mukai H; Horiguchi J; Tokuda Y; Kuroi K; Mori A; Ohno N; Noguchi S
Gan To Kagaku Ryoho; 2015 Jan; 42(1):67-75. PubMed ID: 25596682
[TBL] [Abstract][Full Text] [Related]
15. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
O'Shaughnessy J; Thaddeus Beck J; Royce M
Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
[TBL] [Abstract][Full Text] [Related]
17. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Gnant M; Baselga J; Rugo HS; Noguchi S; Burris HA; Piccart M; Hortobagyi GN; Eakle J; Mukai H; Iwata H; Geberth M; Hart LL; Hadji P; El-Hashimy M; Rao S; Taran T; Sahmoud T; Lebwohl D; Campone M; Pritchard KI
J Natl Cancer Inst; 2013 May; 105(9):654-63. PubMed ID: 23425564
[TBL] [Abstract][Full Text] [Related]
18. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
[TBL] [Abstract][Full Text] [Related]
19. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]